D
Domenico Bonaduce
Researcher at University of Naples Federico II
Publications - 162
Citations - 7221
Domenico Bonaduce is an academic researcher from University of Naples Federico II. The author has contributed to research in topics: Heart failure & Myocardial infarction. The author has an hindex of 38, co-authored 162 publications receiving 5406 citations. Previous affiliations of Domenico Bonaduce include World Allergy Organization & Chartered Institute for Securities & Investment.
Papers
More filters
Journal ArticleDOI
Oxidative stress, aging, and diseases.
Ilaria Liguori,Gennaro Russo,Francesco Curcio,Giulia Bulli,Luisa Aran,David Della-Morte,Gaetano Gargiulo,Gianluca Testa,Gianluca Testa,Francesco Cacciatore,Domenico Bonaduce,Pasquale Abete +11 more
TL;DR: Given the important role of oxidative stress in the pathogenesis of many clinical conditions and aging, antioxidant therapy could positively affect the natural history of several diseases, but further investigation is needed to evaluate the real efficacy of these therapeutic interventions.
Journal ArticleDOI
Cardiotoxicity of immune checkpoint inhibitors
Gilda Varricchi,Maria Rosaria Galdiero,Giancarlo Marone,Gjada Criscuolo,Maria Triassi,Domenico Bonaduce,Gianni Marone,Carlo G. Tocchetti +7 more
TL;DR: The mechanisms of the most prominent checkpoint inhibitors are described, specifically ipilimumab (anti-CTLA-4, the godfather of checkpoint inhibitors) patient and monoclonal antibodies targeting PD-1 and PD-L1 (eg, atezolizumab).
Journal ArticleDOI
Sarcopenia: assessment of disease burden and strategies to improve outcomes.
Ilaria Liguori,Gennaro Russo,Luisa Aran,Giulia Bulli,Francesco Curcio,David Della-Morte,Gaetano Gargiulo,Gianluca Testa,Gianluca Testa,Francesco Cacciatore,Domenico Bonaduce,Pasquale Abete +11 more
TL;DR: Because sarcopenia is associated with important adverse health outcomes, such as frailty, hospitalization, and mortality, several therapeutic strategies have been identified that involve exercise training, nutritional supplementation, hormonal therapies, and novel strategies and are still under investigation.
Journal ArticleDOI
Improved Cardiovascular Risk Factors and Cardiac Performance after 12 Months of Growth Hormone (GH) Replacement in Young Adult Patients with GH Deficiency
Annamaria Colao,Carolina Di Somma,Alberto Cuocolo,Letizia Spinelli,Nicolina Tedesco,Rosario Pivonello,Domenico Bonaduce,Marco Salvatore,Gaetano Lombardi +8 more
TL;DR: In conclusion, GH replacement for 12 months significantly improved lipid profile, decreased fibrinogen levels, and increased LVMi and LVEF in young adults with co- or ao-GHD, suggesting that a longer period of GH replacement is necessary to normalize cardiovascular parameters and reverse the cardiovascular risk of these patients.
Journal ArticleDOI
Effects of converting enzyme inhibition on heart period variability in patients with acute myocardial infarction.
Domenico Bonaduce,Fortunato Marciano,Mario Petretta,M L Migaux,Gianfranco Morgano,Valter Bianchi,Luigi Salemme,Giuseppe Valva,Mario Condorelli +8 more
TL;DR: This study supports the hypothesis that the renin-angiotensin system modulates the amplitude of ULF and VLF power and demonstrates that in MI patients, converting enzyme inhibition favorably modifies measures of heart period variability strongly associated with a poor prognosis.